Collegium Pharmaceutical Inc Stock Price, News & Analysis

Collegium Pharmaceutical (Nasdaq: COLL) has announced its upcoming participation in three major healthcare investor conferences in March 2025. The company's management will engage in investor meetings at the Leerink Partners 2025 Global Healthcare Conference on March 11, the Jefferies Biotech on the Beach Summit on March 12, and the Barclays 27th Annual Global Healthcare Conference on March 13.

Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2024. The company achieved record quarterly revenue of $181.9 million (up 22% YoY) and full-year revenue of $631.4 million (up 11% YoY). Q4 GAAP net income was $12.5 million with record adjusted EBITDA of $107.7 million.

Key product performance included Jornay PM with Q4 net revenue of $29.3 million and pro forma full-year revenue of $100.7 million, showing 29% YoY prescription growth. Belbuca achieved record quarterly revenue of $55.2 million (up 12% YoY), while Xtampza ER posted record revenue of $51.5 million (up 6% YoY).

The company ended 2024 with $162.8 million in cash and equivalents, after completing the $200 million Ironshore Therapeutics acquisition and executing $60 million in share repurchases.

Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its fourth quarter and full-year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Investors can access the call via U.S. dial-in (877) 407-8037 or International dial-in (201) 689-8037. An audio webcast will be available on the company's website investor section and will remain accessible for replay approximately two hours after the event.

Collegium Pharmaceutical (Nasdaq: COLL) has appointed Nancy S. Lurker to its Board of Directors, effective February 4, 2025. Lurker brings significant expertise in commercial growth and strategic acquisitions, having most recently served as President and CEO of EyePoint Pharmaceuticals until 2023, where she now holds the position of Executive-Vice Chair.

Her extensive experience includes roles as President and CEO of PDI, Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals, and President and CEO of ImpactRx. She currently serves on multiple boards, including Alkermes plc and Altasciences, , and advisory boards for Novo Holdings and Stanford Medicine's Master of Science program.

Collegium Pharmaceutical (Nasdaq: COLL) has announced its 2025 financial guidance, projecting product revenues between $735-750 million and adjusted EBITDA of $435-450 million. The company expects Jornay PM, their ADHD treatment, to generate over $135 million in net revenue, positioning it as their primary growth driver.

The company's adjusted operating expenses are anticipated to be between $220-230 million. Recent highlights include completing the Ironshore integration, accelerating Jornay PM prescriptions during the 2024 back-to-school season, and executing a share repurchase program worth $60 million under a $150 million authorization, including $25 million in Q4 2024 and $35 million through an accelerated program in May 2024.

Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Jefferies London Healthcare Conference on November 19, 2024, at 1:30 p.m. GMT and the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, at 1:00 p.m. ET. Both sessions will be accessible via webcast through the company's investor relations website, with recordings available for 90 days post-presentation.

Collegium Pharmaceutical reported strong Q3 2024 financial results with record net revenue of $159.3 million, up 17% year-over-year. The growth was driven by record revenues from Belbuca ($53.2M) and Xtampza ER ($49.5M). The company achieved GAAP net income of $9.3 million and record adjusted EBITDA of $105.1 million, up 18% year-over-year. A significant development was the acquisition of Ironshore Therapeutics, expanding into neurology with Jornay PM, which is expected to generate over $100 million in pro forma net revenue in 2024. The company reaffirmed its 2024 guidance with projected product revenues of $620-635 million.

Collegium Pharmaceutical (COLL) has appointed Vikram Karnani as President and CEO, effective November 12, 2024. Karnani brings over 15 years of life sciences leadership experience, notably from Horizon Therapeutics where he helped grow annual net product sales from $300 million to nearly $4 billion. He succeeds interim CEO Michael Heffernan, who will remain Board Chairman.

The appointment comes as Collegium's pain portfolio achieves record revenue, with Jornay PM positioned as the lead growth driver. Karnani most recently served as Executive VP and President of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, following its acquisition of Horizon in 2023.

Collegium Pharmaceutical has completed the acquisition of Ironshore Therapeutics, adding Jornay PM to its portfolio and establishing a presence in the ADHD market. The deal, valued at $525 million in cash, is expected to be immediately accretive to Collegium's financials. Key highlights include:

1. Jornay PM's net revenue is projected to exceed $100 million in 2024.
2. Updated 2024 guidance: Product Revenues, Net of $620.0-$635.0 million.
3. Adjusted EBITDA expected to be $395.0-$405.0 million.
4. The acquisition was funded by $200 million cash and a $325 million term loan.

This strategic move aligns with Collegium's mission to build a diversified specialty pharmaceutical company, broadening its portfolio beyond pain management.